Cargando…
4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection
BACKGROUND: Chagas disease, caused by the protozoan Trypanosoma cruzi, is the leading cause of heart failure in Latin America. The clinical treatment of Chagas disease is limited to two 60 year-old drugs, nifurtimox and benznidazole, that have variable efficacy against different strains of the paras...
Autores principales: | Calvet, Claudia Magalhaes, Choi, Jun Yong, Thomas, Diane, Suzuki, Brian, Hirata, Ken, Lostracco-Johnson, Sharon, de Mesquita, Liliane Batista, Nogueira, Alanderson, Meuser-Batista, Marcelo, Silva, Tatiana Araujo, Siqueira-Neto, Jair Lage, Roush, William R., de Souza Pereira, Mirian Claudia, McKerrow, James H., Podust, Larissa M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5744913/ https://www.ncbi.nlm.nih.gov/pubmed/29281643 http://dx.doi.org/10.1371/journal.pntd.0006132 |
Ejemplares similares
-
4-Aminopyridyl-Based
CYP51 Inhibitors as Anti-Trypanosoma cruzi Drug Leads with Improved Pharmacokinetic
Profile and in Vivo Potency
por: Calvet, Claudia M., et al.
Publicado: (2014) -
Binding Mode and Potency of N-Indolyloxopyridinyl-4-aminopropanyl-Based
Inhibitors Targeting Trypanosoma cruzi CYP51
por: Vieira, Debora F., et al.
Publicado: (2014) -
Diverse Inhibitor Chemotypes Targeting Trypanosoma cruzi CYP51
por: Gunatilleke, Shamila S., et al.
Publicado: (2012) -
Long term follow-up of Trypanosoma cruzi infection and Chagas disease manifestations in mice treated with benznidazole or posaconazole
por: Calvet, Claudia Magalhães, et al.
Publicado: (2020) -
Structural Characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei Bound to the Antifungal Drugs Posaconazole and Fluconazole
por: Chen, Chiung-Kuang, et al.
Publicado: (2010)